Adult Clinical Trials

For more information about participating in a clinical trial, please contact
Alicia Connelly, our clinical trials coordinator, at (504) 568-3410.

(For an in-depth description of the following trials, please click here.)
*Document last updated on February 3, 2010.

Breast Cancer Trials

IRB #5636: CALGB 40101: Cyclophosphamide and Doxorubicin (CA)(4 vs. 6 cycles) vs. Paclitaxel (4 vs. 6 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase III Randomized Study

IRB #5899: S0221: Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node Positive or High-Risk Node-Negative Breast Cancer

IRB #6389: NSABP B-39/RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

IRB #6700: ECOG; PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning Individualized Options for Treatment

IRB #6733: CALGB 40302: Endocrine Therapy with or without inhibition of EGF and HER2 Growth Factor Receptors: A randomized, double blind placebo-controlled phase III trial of fulvestrant with or without Lapatinib (GW572016) for postmenopausal women with hormone receptor positive advanced breast cancer

IRB #6901: NSABP B-40: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regime

IRB #6942C: E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node positive and High-risk Lymph Node Negative Breast Cancer

IRB #6943C: E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2NEU Overexpressing Metastatic Breast Cancer

IRB #7233C CALGB 70301: Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes

IRB #7310: Z1071: A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis

CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

N063D/BIG 2-06, ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study: A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer

Gastrointestinal Trials (GI)

IRB# 6355: PTKAUS50: An open-label phase II study evaluating the safety and efficacy of daily dosing of PTK787/2Z 222584 with Sandostatin LAR in patients with metastatic neuroendocrine tumors

IRB #6541; E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

IRB #6736: CALGB/SWOG C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the combination of Bevacizumab and Cetuximab for Patients with untreated Metastatic Adenocarcinoma of the colon or rectum

IRB #6868: E3205: Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma

IRB #6935C: S0518: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Vs Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

IRB #6985C: S0600: Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, OR XELOX

IRB# 7131: IMCL CP13-0710: Phase 2, multi center, two-tier study of IMC-A12 in combination with Depot Octreotide in Patients with metastatic, well-or moderately-differentiated Carcinoid or islet cell carcinoma

Genitourinary Trials (GU)

IRB #6867: E2805: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

IRB #6900: E2804: The BEST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination (CTT) with Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma

IRB #6915: RTOG 0526: A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy

IRB #6951C: R0534: A Phase III Trial Trial of Short-term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed-Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy

IRB #6972: CCCWFU 97405: Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men with Prostate Cancer

IRB #7011C: S0421: Phase III Study of Docetaxel and Atrasentan vs. Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer

IRB #7111C: CALGB 90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer

IRB #7214C: CALGB 90202: A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone

IRB# 7215C: E3805: CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease Prostate Cancer

CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer

Gynecology Trials

CCCWFU 97106: A Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors - (OPEN ONLY TO MINORITIES)

Head and Neck Cancer Trials

IRB #7079C: E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Lung Trials

IRB #5486: S9925 Lung Cancer Specimen Cancer Specimen Repository Protocol, Ancillary

IRB #6873C: RTOG 0617, NCCTG N0628, CALGB 30609: A Randomized Phase III Comparison of Standard Dose (60 Gy) vs High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

IRB #6937C: E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>4 cm) – IIIA Non-Small Cell Lung Cancer

IRB# 7238: 20070782: A randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin Alpha administered at 500µg once-every-3-weeks in anemic subjects with advanced stage non-small cell lung cancer receiving multi-cycle chemotherapy

IRB #7239: S0802, "A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)"

IRB #7297C: S0819, "A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)"

CALGB 30607: Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib, as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Lymphoma Trials

IRB #1576: S8947: Central Lymphoma Serum Repository Protocol (Ancillary)

Melanoma Trials

IRB #7287: S0826, "A Phase II Study of SCH 727965 in Stage IV Melanoma"

 
Myeloma Trials

CALGB 70604: A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
 

Miscellaneous

CCCWFU 97106: A Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors (OPEN ONLY TO MINORITIES)

IRB# 7217: MIP-lb12b: Phase II study evaluating the efficacy and safety of Ultratrace™ Iogenguane I 131 in patients with malignant relapsed refractory Pheochromocytoma/Paraganglioma